Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial

P. P. Tak, P. J. Mease, M. C. Genovese, J. Kremer, B. Haraoui, Y. Tanaka, C. O. Bingham, A. Ashrafzadeh, H. Travers, S. Safa-Leathers, S. Kumar, W. Dummer

Research output: Contribution to journal › Article › peer-review

55 Scopus citations

Fingerprint

Dive into the research topics of 'Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial'. Together they form a unique fingerprint.

Medicine & Life Sciences